BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage develop…
Biotechnology
US, Palo Alto [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 66.78 | 5.54 | 3.32 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 2812.92 | 234.77 | -8.06 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 24.34 | -5.87 | -7.76 | |
| Cash | 16.69 | 2.91 | 2.49 | |
| Capex | -234.84 | < 0.005 | < 0.005 | |
| Free Cash Flow | -72.27 | -1.24 | -0.72 | |
| Revenue | 11711.31 | 1.18 | 0.01 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 50.77 | 0.99 | 0.66 | |
| Operating Margin | -99.98 | 0.02 | -101.67 | |
| ROA | 86.53 | -0.04 | -0.31 | |
| ROE | -72.98 | 0.03 | 0.12 | |
| ROIC | -98.93 | < 0.005 | -0.51 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of BBIO is permitted for members.
5
Growth
The "Growth Entry" for the Focus of BBIO is permitted for members.
6
Leverage & Liquidity